Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents

  title={Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents},
  author={Deborah C. Mash and Barbara Ameer and Delphine Prou and John F. Howes and Emeline L. Maillet},
  journal={Journal of Psychopharmacology},
  pages={688 - 697}
This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of vehicle control with an ED50 of 13 mg/kg. In the second experiment, blood and brain levels of noribogaine… 

Figures and Tables from this paper

A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats.
It is found that ibogaine and noribogaine induced a dose- and time-dependent antidepressant-like effect without significant changes of animal locomotor activity, which suggests a polypharmacological mechanism underpinning the antidepressant- like effects of ibogane and norIBogaine.
DARK Classics in Chemical Neuroscience: Ibogaine.
Structural-activity studies led to the isolation of the ibogaine analog 18-methoxycoronaridine (18-MC), an α3β4 nicotinic receptor modulator that retains ibogane's anticraving properties with few or no adverse effects.
Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report
It is not clear if ibogaine at low doses could be used therapeutically in people on methadone maintenance treatments (MMT), but a case report of a female on MMT for 17 years who performed a self-treatment with several low and cumulative doses of ibogance over a 6-week period successfully eliminated her withdrawal symptoms.
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
It is reported here that ibogaine therapy administered in a safe dose range diminishes opioid withdrawal symptoms and reduces drug cravings and product development of single oral dose administration of Ibogaine for the treatment of opioid withdrawal during medically supervised detoxification to transition drug dependent individuals to abstinence is supported.
Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence
Evidence from preclinical and human studies that administered drugs acting on the dopamine, serotonin, cannabinoid, orexin/hypocretin, and glutamate systems and reported outcomes related to opioid withdrawal support a focused examination of mechanistically informed concomitant medications to help reduce opioid withdrawal severity and enhance the continuum of care available for persons with OUD.
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful, and may provide a useful prototype for discovery and development of innovative pharmacotherapy of addiction.
Ibogaine offers an alternative approach for treating opiate addiction
Ibogaine is a naturally occurring indole alkaloid that may be an effective alternative form of treatment for individuals struggling with opiate addiction and/or withdrawal and is found that iboga alkaloids such as ibogaine are effective at reducing morphine self-administration in rats.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
Ibogaine’s legal availability in New Zealand may offer improved outcomes where legislation supports treatment providers to work closely with other health professionals.
Breaking the cycle of opioid use disorder with Ibogaine
  • Deborah C Mash
  • Medicine
    The American journal of drug and alcohol abuse
  • 2018
Two studies demonstrate that ibogaine may have significant pharmacological effects that include blockade of the acute signs and symptoms of opioid withdrawal (SOWS) and the post-acute withdrawal syndrome (cravings and depression).
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
It is concluded that the kappa opioid field will benefit tremendously from future studies that compare several biased agonists and correlate the degree of signaling bias to a particular pharmacological response.


Noribogaine reduces nicotine self-administration in rats
It is suggested that noribogaine dose-dependently attenuates drug-taking behavior for nicotine, attenuates the reinforcing effects of nicotine and is comparable to varenicline power in that regard.
Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.
Effects and aftereffects of ibogaine on morphine self-administration in rats.
Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-d-aspartate receptors
NMDA antagonist properties of the putative antiaddictive drug, ibogaine.
Findings link the NMDA antagonist actions of ibogaine to a putative "antiaddictive" property of this alkaloid, its ability to reduce the expression of morphine dependence.
Effects of ibogaine on acute signs of morphine withdrawal in rats: Independence from tremor
Noribogaine is a G-protein biased κ-opioid receptor agonist
Indirect serotonergic agonists attenuate neuronal opiate withdrawal
Noribogaine (12‐Hydroxyibogamine): A Biologically Active Metabolite of the Antiaddictive Drug Ibogaine
The present data demonstrate that NORIBO is biologically active and undoubtedly contributes to the in vivo pharmacological profile of IBO in rats, and appears less likely to produce the adverse effects associated with IBO (i.e., tremors and stress‐axis activation), suggesting that the metabolite may be a safer alternative for medication development.